Corbus Pharmaceuticals Holdings (CRBP) Other Non-Current Assets (2014 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Other Non-Current Assets of $1.8 million for Q4 2025, up 368.83% year-over-year from $385000.0 in Q4 2024, and up 368.83% quarter-over-quarter from $385000.0 in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Other Non-Current Assets (2014 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Other Non-Current Assets history runs 12 years deep, the most recent figure standing at $1.8 million for Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 368.83% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $1.8 million (up 368.83% YoY), while the FY2025 annual figure was $1.8 million, up 368.83% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $1.8 million, up from $385000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.8 million in Q4 2025, with the low at $384950.0 in Q1 2024.
- The 5-year median for Other Non-Current Assets is $477425.0 (2021), against an average of $554228.8.
- Peak annual rise in Other Non-Current Assets reached 4656.12% in 2021, while the deepest fall reached 53.19% in 2021.
- Corbus Pharmaceuticals Holdings' Other Non-Current Assets stood at $477425.0 in 2021, then changed by 0.0% to $477425.0 in 2022, then grew by 0.12% to $478000.0 in 2023, then dropped by 19.46% to $385000.0 in 2024, then surged by 368.83% to $1.8 million in 2025.
- Business Quant data shows CRBP's Other Non-Current Assets at $1.8 million in Q4 2025, $385000.0 in Q3 2025, and $385000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | 1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | 385,000.00 |
| Jun 30, 2025 | 385,000.00 |
| Mar 31, 2025 | 385,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Sep 30, 2024 | 670,000.00 |
| Jun 30, 2024 | 670,000.00 |
| Mar 31, 2024 | 384,950.00 |
| Dec 31, 2023 | 478,000.00 |
| Sep 30, 2023 | 477,425.00 |
| Jun 30, 2023 | 477,425.00 |
| Mar 31, 2023 | 477,425.00 |
| Dec 31, 2022 | 477,425.00 |
| Sep 30, 2022 | 477,425.00 |
| Jun 30, 2022 | 477,425.00 |
| Mar 31, 2022 | 477,425.00 |
| Dec 31, 2021 | 477,425.00 |
| Sep 30, 2021 | 477,425.00 |
| Jun 30, 2021 | 569,900.00 |
| Mar 31, 2021 | 669,900.00 |